A post by @FirstSquawk on X.
MERCK ANNOUNCES POSITIVE RESULTS FROM A PHASE 2B TRIAL OF EFINOPEGDUTIDE IN ADULTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND STAGE 2-3 FIBROSIS, SAYING THE DRUG DEMONSTRATED IMPROVEMENT IN LIVER FIBROSIS WITHOUT…
@FirstSquawk on X
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
The trial enrolled patients with advanced fibrosis, the population where MASH drug development has historically struggled. The readout matters because fibrosis improvement is the endpoint regulators and investors view as the clearest sign of disease modification in MASH. Merck did not disclose detailed response rates or safety data in the initial announcement. Watch for full efficacy and tolerability data, and how the profile compares with rival MASH therapies, as Merck weighs late-stage development.
Muhabbit's AI wrote this summary of @FirstSquawk's post in its own words. It can get details wrong, so read the post on X.
Named in this story
Merck (MRK), efinopegdutide
A linked name opens that asset's sentiment page.